Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AdaptHealth Corp (AHCO) vs Eli Lilly And Co (LLY) Price & Performance

AdaptHealth CorpTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

AdaptHealth Corp vs Eli Lilly And Co — how do they compare? AdaptHealth Corp trades at $5.83 (market cap $753.09M), while Eli Lilly And Co trades at $1,222.99 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 1434.1× AdaptHealth Corp's market cap, and Eli Lilly And Co pays a 0.57% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.

AHCOLLY
Market Cap
$753.09M$1.08T
Sector
HealthHealth
52-Week High
$13.38$1.24K
52-Week Low
$5.22$639.43
Enterprise Value
$2.77B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AdaptHealth Corp

AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.

The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AdaptHealth Corp

AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.

Read more on AHCO

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY